EPO and neoplasm: Other pharmacological strategies base on vessel promotion, with, e.g., recombinant human erythropoietin (Epo) or cilengitide, both inducing an increase in vessel density and in the relative blood volume and by this enhance drug delivery to the tumor site (Bridges and Harris, 2015; Doleschel et al., 2015; Wong et al., 2015; Nel et al., 2017).